ISMEN:BISTIs Yatirim Menkul Degerler AS Analysis
Data as of 2026-06-12 - not real-time
TRY 36.18
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ISMEN is trading at 36.18 TRY, well under its 20‑day (37.76), 50‑day (40.63) and 200‑day (42.81) simple moving averages, signaling a short‑term bearish bias. The 14‑day RSI of 32.9 indicates the stock is in oversold territory, while the MACD line remains below its signal, reinforcing downside momentum. Volatility over the past 30 days is elevated at ~28 %, but the beta is essentially flat (≈0.03), suggesting market‑wide moves have limited impact on price. Trading volume is rising, providing decent liquidity despite the price pressure. Recent KAP filings disclose new warrant and certificate issuances, but they do not materially alter the company’s earnings outlook.
On the valuation side, ISMEN’s trailing PE of 7.99 is far below the sector average of 16.8, and its price‑to‑book of 1.68 is modest. The DCF model implies a fair value of roughly 296 TRY, and the consensus target price of 68 TRY indicates an upside of over 80 % from current levels. The firm generates a high dividend yield of 8.85 % with a payout ratio near 70 %, supported by strong operating cash flow and a net cash position of ~56 bn TRY. Revenue is expanding at 13.5 % YoY, though margins remain thin (gross 1.68 %, net 0.4 %). Debt‑to‑equity sits at 62.5 %, balanced by ample cash, limiting financial distress risk. The combination of cheap valuation, attractive yield, and solid cash flow points to a fundamentally undervalued position. However, the technical picture remains bearish, so investors should weigh short‑term price weakness against long‑term value upside.
On the valuation side, ISMEN’s trailing PE of 7.99 is far below the sector average of 16.8, and its price‑to‑book of 1.68 is modest. The DCF model implies a fair value of roughly 296 TRY, and the consensus target price of 68 TRY indicates an upside of over 80 % from current levels. The firm generates a high dividend yield of 8.85 % with a payout ratio near 70 %, supported by strong operating cash flow and a net cash position of ~56 bn TRY. Revenue is expanding at 13.5 % YoY, though margins remain thin (gross 1.68 %, net 0.4 %). Debt‑to‑equity sits at 62.5 %, balanced by ample cash, limiting financial distress risk. The combination of cheap valuation, attractive yield, and solid cash flow points to a fundamentally undervalued position. However, the technical picture remains bearish, so investors should weigh short‑term price weakness against long‑term value upside.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price near support at 35 TRY
- Bearish technical indicators (SMAs, MACD)
- High dividend yield provides downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap vs industry (PE 7.99 vs 16.8)
- Strong cash position and moderate debt
- Attractive dividend yield with sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value indicates large upside
- Consistent revenue growth and solid ROE
- Low beta reduces market‑wide volatility exposure
Key Metrics & Analysis
Financial Health
Revenue Growth13.50%
Profit Margin0.40%
P/E Ratio8.0
ROE22.84%
ROA5.46%
Debt/Equity62.52
P/B Ratio1.7
Op. Cash FlowTRY25.6B
Industry P/E16.8
Technical Analysis
TrendBearish
RSI32.9
SupportTRY 35.00
ResistanceTRY 40.92
MA 20TRY 37.76
MA 50TRY 40.63
MA 200TRY 42.81
MACDBearish
VolumeIncreasing
Fear & Greed Index88.45
Valuation
Fair ValueTRY 295.66
Target PriceTRY 68.07
Upside/Downside88.13%
GradeUndervalued
TypeValue
Dividend Yield8.85%
Risk Assessment
Beta0.03
Volatility28.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.